Biolinq Raises $100Mn in Series C Funding for Wearable Glucose Sensors

Biolinq has developed a wearable patch to assess glucose levels and provide metabolic health insights for individuals with type 2 diabetes not on insulin.

US-based Biolinq, a healthcare technology company, has secured $100 million in a Series C funding round led by Alpha Wave Ventures.

The round also saw participation from existing investors, including AXA IM Alts, M Ventures, LifeSci Venture Partners, RiverVest Venture Partners, Hikma Ventures, Taisho Pharmaceutical, Features Capital, and Aphelion Capital.

Biolinq has developed a wearable patch to assess glucose levels and provide metabolic health insights for individuals with type 2 diabetes not on insulin.

The patch utilizes small electrochemical sensors to measure glucose levels from the intradermal space beneath the skin's surface. However, the company's glucose sensor remains under investigation and has not yet received FDA clearance or approval.

Rich Yang, CEO of Biolinq, said, "This financing will bolster Biolinq's commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device."

Over the past year, Biolinq secured $58 million in funding for FDA submissions and clinical trials for its glucose sensor.

Before this, the company raised $4.75 million in extended Series A financing in 2019 and received $20 million in Series A funding in 2017.

Stay tuned for more such updates on Digital Health News.

Stay tuned for more such updates on Digital Health News